The emergence of monoclonal antibodies (mAbs) against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death 1 receptor (PD-1), and its ligand, PD-L1, has revolutionized the treatment landscape of cancer (1). This evidence concerns the gene CTLA4 and cancer.